Icatibant Zentiva

Icatibant acetate, the active ingredient in Icatibant Zentiva, is a bradykinin B2 receptor antagonist presented as a solution for subcutaneous injection use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency, providing rapid reduction of swelling.

GNH USA supplies Icatibant Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides cold‑chain logistics for injectable products. Clients benefit from reliable delivery timelines and regulatory support across multiple regions.

Icatibant Zentiva acts as a competitive antagonist of the bradykinin B2 receptor, targeting the bradykinin pathway to treat hereditary angioedema. - Hereditary angioedema (C1‑inhibitor deficiency): provides rapid relief of swelling during acute attacks. - Hereditary angioedema type I: reduces symptom severity and duration of episodes. - Hereditary angioedema type II: improves patient outcomes by limiting airway compromise. - Hereditary angioedema with abdominal attacks: alleviates painful gastrointestinal swelling.

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling at injection site: localized erythema or edema. - Headache: transient headache occurring after administration. - Nausea: occasional feeling of nausea without vomiting.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema of the face or throat: potentially life‑threatening swelling. - Hypotension: sudden drop in blood pressure that may cause dizziness.

When prescribing Icatibant, clinicians should consider several safety precautions. - Pregnancy: safety has not been established; use only if benefit outweighs risk. - Breastfeeding: unknown safety; weigh potential benefits against possible infant exposure. - Renal impairment: use with caution, as clearance may be reduced. - Concomitant ACE inhibitors: monitor for enhanced bradykinin effects that could diminish efficacy. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence the bradykinin system or its metabolism.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and reduce Icatibant effectiveness. - Neprilysin inhibitors (e.g., sacubitril): can elevate bradykinin, potentially diminishing therapeutic response.

Moderate Interactions (Monitor Closely): - DPP‑4 inhibitors: may modestly raise bradykinin concentrations; monitor clinical response. - Estrogen‑containing oral contraceptives: could affect bradykinin metabolism; observe for altered efficacy. - Other B2 receptor antagonists: concurrent use may lead to additive effects; adjust therapy as needed.